{"doi":"10.1016/j.ejogrb.2025.114877","title":"Metabolomics reveals pre-eclamptic-protective mechanisms within individuals","abstract":"OBJECTIVES: Pre-eclampsia is a common and dangerous hypertensive pregnancy complication, with recurrence in as many as 80% of subsequent pregnancies. However, it is often difficult to predict recurrence. Further complicating risk assessment and biomarker development, the genetic and environmental drivers of pre-eclampsia are varied and numerous. In this study, a longitudinal, repeated-measures design was used to control for many of these drivers, and to isolate factors that may be associated with pre-eclampsia in subsequent pregnancies. STUDY DESIGN: In an exploratory cohort (n = 14) of individuals who had a pregnancy affected by pre-eclampsia and then had an immediate subsequent pregnancy without pre-eclampsia, late-gestation circulating metabolomics were evaluated utilizing a targeted (83 analytes) metabolomics profiling approach. Metabolites were extracted from maternal plasma samples collected from successive pregnancies. MAIN OUTCOME MEASURES: Derivatized samples were analysed by gas chromatography-mass spectroscopy, and metabolites were identified and annotated in accordance with reference standards. All data were normalized ratiometrically and scaled uniformly. RESULTS: Exploratory comparisons of pre-eclamptic and non-pre-eclamptic pregnancies revealed significant differences in inositol, methyl citrate, gamma-aminobutyric acid (GABA) and cysteine levels. Metabolite set quantitative enrichment analysis showed that pyruvate metabolism was potentially enriched among metabolites changed by pre-eclamptic status. CONCLUSIONS: These findings demonstrate that metabolomic changes within individuals may biomark subsequent risk for pre-eclampsia, and specific metabolites may prove to be successful targets for future studies of pre-eclamptic therapeutics.","journal":"European Journal of Obstetrics & Gynecology and Reproductive Biology","year":2025,"id":584189,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9541,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":702007,"name":"Brandon Schickling","orcid":"0000-0002-2312-268X","position":1,"is_corresponding":false},{"id":257538,"name":"Donna A. Santillan","orcid":"0000-0002-6180-9714","position":2,"is_corresponding":false},{"id":257539,"name":"Mark K. Santillan","orcid":"0000-0002-3991-8017","position":3,"is_corresponding":false},{"id":257537,"name":"Serena B. Gumusoglu","orcid":"0000-0002-2098-388X","position":0,"is_corresponding":true}],"reference_count":38,"raw_metadata":null,"created_at":"2026-07-19T02:59:11.978098Z","pmid":"41353857","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}